• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.03% Nasdaq Up0.33%

    Conatus Pharmaceuticals Inc. (CNAT)

    4.82 Down 0.11(2.23%) Jul 30, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Conatus Pharmaceuticals Inc.
    16745 West Bernardo Drive
    Suite 200
    San Diego, CA 92121
    United States - Map
    Phone: 858-376-2600
    Website: http://www.conatuspharma.com

    Index Membership:N/A
    Full Time Employees:25

    Business Summary 

    Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Conatus Pharmaceuticals Inc.

    Key Executives 
    Dr. Steven J. Mento Ph.D., 63
    Co-Founder, Chief Exec. Officer, Pres and Director
    Dr. Alfred P. Spada Ph.D., 57
    Co-Founder, Chief Scientific Officer and Exec. VP of R&D
    Dr. David T. Hagerty M.D., 60
    Exec. VP of Clinical Devel.
    Mr. Charles J. Cashion MBA, 64
    Co-Founder, Chief Financial Officer, Sr. VP of Fin. and Sec.
    Mr. Daniel L. Ripley MBA, 54
    VP of Bus. Devel. & Program Management
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders